In this study, we identified BCL2L1 (BCL-XL) as a key node in determining sensitivity (Figure 4) and further showed that inhibition of the BCL-2 family by the small-molecule inhibitor, ABT-737, enhances TRAIL-induced toxicity in breast cancer cell lines (Figure 7C). Here, BCL2L1 is linked to breast carcinoma.